• Latest
  • Trending
  • All
  • News
  • BUSINESS
  • SCIENCE
  • LIFESTYLE
  • TECH
J.P. Morgan Says the Stock Market Is Poised for More Upside; Here Are 2 Stocks the Banking Giant Likes

J.P. Morgan Says the Stock Market Is Poised for More Upside; Here Are 2 Stocks the Banking Giant Likes

August 16, 2022
Daily Crunch: After raising $3M seed, global fintech platform Payday plans to secure licensing in Canada, UK

Daily Crunch: After raising $3M seed, global fintech platform Payday plans to secure licensing in Canada, UK

March 29, 2023
Jennifer Aniston Says ‘Friends’ Is Now Deemed ‘Offensive’: Interview – Hollywood Life

Jennifer Aniston Says ‘Friends’ Is Now Deemed ‘Offensive’: Interview – Hollywood Life

March 29, 2023
Salmon Tempura Crunch Bowls | Cup of Jo

Salmon Tempura Crunch Bowls | Cup of Jo

March 29, 2023
A Spike In Supply Could Tank Multifamily Prices This Year

A Spike In Supply Could Tank Multifamily Prices This Year

March 29, 2023
Benson Hill Announces Preliminary Unaudited 2022 Results and … – Business Wire

MULTIMEDIA RELEASE: Coast Guard crew offloads $166 million … – U.S. Coast Guard

March 29, 2023
How to End Bias and Taboos in Women’s Health Care

How to End Bias and Taboos in Women’s Health Care

March 29, 2023
Apple’s iOS 17 gets official on June 5

Apple’s iOS 17 gets official on June 5

March 29, 2023
PS5 launch title ‘Sackboy’ is free on PlayStation Plus in April

PS5 launch title ‘Sackboy’ is free on PlayStation Plus in April

March 29, 2023
Putin in Mariupol

Putin in Mariupol

March 29, 2023
EA laying off 6% of staff in cost-cutting push for videogame publisher

EA laying off 6% of staff in cost-cutting push for videogame publisher

March 29, 2023
Is the US Preparing for the “NATOization” of Bosnia?

Why the Repeal of Anti-Union Laws in Michigan Boosts Workers Nationwide

March 29, 2023
FDIC plans to return $4B in Signature crypto deposits ‘by early next week’ — Martin Gruenberg

FDIC plans to return $4B in Signature crypto deposits ‘by early next week’ — Martin Gruenberg

March 29, 2023
  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds
No Result
View All Result
No Result
View All Result
Home BUSINESS

J.P. Morgan Says the Stock Market Is Poised for More Upside; Here Are 2 Stocks the Banking Giant Likes

by Minnesota Digital News
August 16, 2022
in BUSINESS
0
J.P. Morgan Says the Stock Market Is Poised for More Upside; Here Are 2 Stocks the Banking Giant Likes
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter


The big question on investors’ minds right now is, where will inflation go? And the related follow-up question, for everyone, is, how far will the Fed hike rates in response? The potential answers cover the full range of possibilities, from President Biden’s happy talk about ‘zero percent inflation,’ to the market bears predicting a full-blown economic depression.

Count JPMorgan’s chief asset management strategist David Kelly among the bulls. He’s not convinced by the doomsayers, and sees the recent drop in inflation as a sign that the worst is getting behind us. While current conditions are still hard, Kelly believes that the stock market can and will show additional strength going forward. In his words, “I would be fully invested in equities at this point because I do think that equities can move higher here.”

So let’s follow JPM a little further down this trail. The banking giant’s stock analysts have picked out two stocks that they believe are ready to surge ahead – by the order of 40% or more. In fact, the JPM experts are not the only ones singing these stocks’ praises. According to the TipRanks platform – they are rated as Strong Buys by the Street’s analysts. Let’s take a closer look.

BeiGene (BGNE)

The first JPM pick is BeiGene, a clinical-stage biopharmaceutical company, with, in its words, ‘a broad and deep pipeline’ that takes a shotgun approach to the field of oncology. The company is developing a tremendous number of drug candidates, more than 50, both in-house and as collaborative efforts, to address treatment needs in some 80% of cancer malignancies. A pipeline that size gives the company a competitive advantage when compared to peers.

BeiGene is a truly international biotech firm, operating in Asia, in Europe, and in the Americas, and boasting administrative offices in Beijing, China, Cambridge, Massachusetts, and Basel, Switzerland. From these offices, the company oversees its development activities, and the commercialization activities for its line of approved commercial-stage products.

The leading approved products are zanubrutinib, branded as Brukinsa, pamiparib, branded as Partruvix, and tislelizumab, branded under its own name. As a group, these drugs are approved in several international jurisdictions for the treatment of various hematological cancers and solid tumors. BeiGene has been actively commercializing them for several years now, and in 2Q22 the company realized $304.5 million in total sales revenue. This number included $128.7 million from Brukinsa and $104.9 million in sales of tislelizumab in China. The company’s total revenue, which includes collaboration fees, reached $341.6 million, compared to $150 million in the year-ago quarter.

Covering the stock for JPMorgan, analyst Xiling Chen believes BGNE presents a compelling risk reward. Kumar rates the stock an Overweight (i.e. Buy) along with a $296 price target that implies a 50% one-year upside.

Backing his bullish stance, Chen writes: “We see BeiGene shares as undervalued given quality of assets/growth and highlight the stock as one of our top picks in the sector… BeiGene has grown into a fully integrated biopharma company with best-in-class clinical development capabilities, one of the largest and best oncology commercial platforms in China, and unmatched partnership skills with global biopharma companies. We expect the company’s 16 commercial assets and broad pipeline to drive very attractive, diversified long-term growth. While we remain moderately below consensus on long-term sales, we see additional pipeline traction as upside to our estimates…”

Overall, 6 Wall Street analysts have chimed in on this biotech giant, and left 5 Buy recommendations against 1 Hold for a Strong Buy consensus rating. The shares are priced at $192.77 and their $253.76 average price target indicates an upside potential of ~29% in the coming months. (See BGNE stock forecast on TipRanks)

Xenon Pharmaceuticals (XENE)

The second stock we’re looking at is Xenon, another biopharma firm at the clinical stage. Xenon is working on new therapeutic agents in the field of neurology, looking for novel drugs to treat neurological conditions with high unmet medical needs. The company has a particular focus on treatments for epilepsy.

Xenon has two leading drug candidates in this field, XEN496 and XEN1101, at Phase 3 and Phase 2 trials stages respectively. XEN496 is Kv7 potassium channel opener, and is being investigated for a rare pediatric form of epileptic seizure disorder. The company expects to complete the Phase 3 EPIK study of XEN496 during 2023.

XEN1101, however, is the company’s flagship drug candidate. It is currently undergoing several Phase 2 trials, for focal onset seizure epilepsy (FOS), primary generalized tonic-clonic seizures (PGTCS), and major depression. The Phase 2b X-TOLE trial, against FOS, is expected to be completed this year, and the company has two identical Phase 3 trials, X-TOLE2 and X-TOLE3, in preparation to run when the current trial is completed. The Phase 3 trials will run in parallel and enroll up to 360 patients.

Xenon is also planning the X-ACKT Phase 3 trial, to continue its study of XEN1101’s efficacy against PGTCS. This study will run simultaneously with the X-TOLE trials.

Finally, Xenon has the Phase 2 X-NOVA study ongoing to evaluate XEN1101 against major depressive disorder. Topline results from this X-NOVA study, which has enrolled 150 patients, are expected in 2023.

JPM analyst Tessa Romero sees XEN1101 as the key factor in this stock, and lays out a clear case why: “Bolstered primarily by compelling phase 2b X-TOLE data as well as positive physician feedback, we view XEN1101 as having a high probability of success as an adjunctive treatment in its lead indication of focal onset seizures (FOS). At the same time, we also see the potential for XEN1101 to work in both patients with focal and/or generalized seizures and forecast ~$1B in peak sales in the U.S. alone in the combined epilepsy indications (~$700M of which is FOS) where our estimates could prove conservative.”

“We believe there is an opportunity in XENE shares at current levels which under-reflect the potential of XEN1101 to expand to additional high unmet need indications beyond FOS where there is convincing emerging rationale,” the analyst added.

Romero rates shares in XENE as Overweight (i.e. Buy), and her $55 price target implies a 46% upside by the end of next year. (To watch Romero’s track record, click here)

Wall Street is clearly upbeat on this biopharma, as all 8 of the recent analyst reviews are positive – for a unanimous Strong Buy consensus rating. The stock is selling for $37.57 and its $51 average price target suggests ~36% one-year upside potential. (See Xenon stock forecast on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.



Source link

Share196Tweet123Share49
Minnesota Digital News

Minnesota Digital News

Saint Paul
◉
28°
Sunny
6:58 am7:35 pm CDT
Feels like: 19°F
Wind: 10mph W
Humidity: 34%
Pressure: 30.37"Hg
UV index: 2
ThuFriSatSun
41/36°F
41/23°F
36/23°F
50/32°F
Weather forecast Saint Paul, Minnesota ▸
Daily Crunch: After raising $3M seed, global fintech platform Payday plans to secure licensing in Canada, UK
TECH

Daily Crunch: After raising $3M seed, global fintech platform Payday plans to secure licensing in Canada, UK

by Minnesota Digital News
March 29, 2023
Jennifer Aniston Says ‘Friends’ Is Now Deemed ‘Offensive’: Interview – Hollywood Life
ENTERTAINMENT

Jennifer Aniston Says ‘Friends’ Is Now Deemed ‘Offensive’: Interview – Hollywood Life

by Minnesota Digital News
March 29, 2023
Salmon Tempura Crunch Bowls | Cup of Jo
LIFESTYLE

Salmon Tempura Crunch Bowls | Cup of Jo

by Minnesota Digital News
March 29, 2023
A Spike In Supply Could Tank Multifamily Prices This Year
REAL ESTATE

A Spike In Supply Could Tank Multifamily Prices This Year

by Minnesota Digital News
March 29, 2023
Benson Hill Announces Preliminary Unaudited 2022 Results and … – Business Wire
PRESS RELEASE

MULTIMEDIA RELEASE: Coast Guard crew offloads $166 million … – U.S. Coast Guard

by Minnesota Digital News
March 29, 2023
How to End Bias and Taboos in Women’s Health Care
SCIENCE

How to End Bias and Taboos in Women’s Health Care

by Minnesota Digital News
March 29, 2023
Apple’s iOS 17 gets official on June 5
MOBILE

Apple’s iOS 17 gets official on June 5

by Minnesota Digital News
March 29, 2023
PS5 launch title ‘Sackboy’ is free on PlayStation Plus in April
GADGET

PS5 launch title ‘Sackboy’ is free on PlayStation Plus in April

by Minnesota Digital News
March 29, 2023
Putin in Mariupol
APPS

Putin in Mariupol

by Minnesota Digital News
March 29, 2023
EA laying off 6% of staff in cost-cutting push for videogame publisher
MARKET

EA laying off 6% of staff in cost-cutting push for videogame publisher

by Minnesota Digital News
March 29, 2023
Is the US Preparing for the “NATOization” of Bosnia?
ECONOMY

Why the Repeal of Anti-Union Laws in Michigan Boosts Workers Nationwide

by Minnesota Digital News
March 29, 2023
FDIC plans to return $4B in Signature crypto deposits ‘by early next week’ — Martin Gruenberg
CRYPTO

FDIC plans to return $4B in Signature crypto deposits ‘by early next week’ — Martin Gruenberg

by Minnesota Digital News
March 29, 2023
Eleone Dance Theatre 2016 Promotional Reel
ARTS & THEATER

Eleone Dance Theatre 2016 Promotional Reel

by Minnesota Digital News
March 29, 2023
Benson Hill Announces Preliminary Unaudited 2022 Results and … – Business Wire
PRESS RELEASE

Press Release | Press Releases | Newsroom | U.S – Senator Dick Durbin

by Minnesota Digital News
March 29, 2023
Congress Finds Time To Yell At Sony On Microsoft’s Behalf
GAMING

Congress Finds Time To Yell At Sony On Microsoft’s Behalf

by Minnesota Digital News
March 29, 2023
Las Vegas Strip Rated One Of Most Photographed Roads In US
Gambling

Consumer Habits Changing With Las Vegas Implications

by Minnesota Digital News
March 29, 2023
Keanu Reeves Made An Absurd Amount Per Word for John Wick 4
MOVIE

Keanu Reeves Made An Absurd Amount Per Word for John Wick 4

by Minnesota Digital News
March 29, 2023
Pussy Riot’s Nadya Tolokonnikova Placed on Russia’s Wanted List
MUSIC

Pussy Riot’s Nadya Tolokonnikova Placed on Russia’s Wanted List

by Minnesota Digital News
March 29, 2023
RRR Highlights – 2023 – USA Theatre Reaction, America, NTR, Ram Charan, S S Rajamouli, M M KEERAVANI
SHOWS

RRR Highlights – 2023 – USA Theatre Reaction, America, NTR, Ram Charan, S S Rajamouli, M M KEERAVANI

by Minnesota Digital News
March 29, 2023
Minnesota Digital News

Copyright © 2023 Minnesota Digital News

Navigate Site

  • Disclaimer
  • Privacy Policy
  • Copyright Notice
  • Anti Spam Policy
  • Medical Disclaimer
  • DMCA Compliance
  • Terms and Conditions
  • Social Media Disclaimer
  • Amazon Affiliate disclaimer

Follow Us

No Result
View All Result
  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds

Copyright © 2023 Minnesota Digital News